.png){kind=icon}
.png){kind=icon}
Return
Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation
.png){kind=icon}
PRE
AI
F
C
F
M
A
M
A
G
A
A
G
O
M
DOI：10.1016/j.medj.2026.101189.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Durvalumab plus chemotherapy is a first-line standard in advanced CCA • FGFR2 and IDH1 inhibitors improve outcomes in selected tumors • Early genomic profiling reduces attrition and supports trial enrollment • Testing and access gaps, especially in LMICs, limit real-world benefit
Journal
IF:
11.8
Papers:
771
Citations:
2.2K
Organization
Cited Papers